Patents by Inventor Marie-Angélique CAZALIS

Marie-Angélique CAZALIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and kit for making an in vitro prognosis of severity for a patient in septic shock
    Patent number: 11377690
    Abstract: The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 5, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: Marie-Angelique Cazalis, Maud Tournoud, Fabienne Venet, Alain Lepape, Guillaume Monneret
  • Methods for determining a patient's susceptibility of contracting a nosocomial infection and for establishing a prognosis of the progression of septic syndrome
    Patent number: 11299768
    Abstract: A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.
    Type: Grant
    Filed: January 18, 2010
    Date of Patent: April 12, 2022
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: Marie-Angelique Cazalis, Alain Lepape, Guillaume Monneret, Bruno Mougin, Alexandre Pachot
  • ASSESSMENT OF THE RISK OF COMPLICATION IN A PATIENT SUSPECTED OF HAVING AN INFECTION, HAVING A SOFA SCORE LOWER THAN TWO
    Publication number: 20210165003
    Abstract: A method for the in vitro or ex vivo assessment of the risk of complications in a patient suspected of having an infection, having a SOFA score of less than two, including measuring the level of expression, in a biological sample obtained from said patient, of at least one expression product of the VEGFR2 gene.
    Type: Application
    Filed: April 15, 2019
    Publication date: June 3, 2021
    Applicant: BIOMÉRIEUX
    Inventors: Marie-Angélique CAZALIS, Karine KAISER, Alexandre PACHOT
  • METHOD AND KIT FOR MAKING AN IN VITRO PROGNOSIS OF SEVERITY FOR A PATIENT IN SEPTIC SHOCK
    Publication number: 20160017423
    Abstract: The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.
    Type: Application
    Filed: January 10, 2014
    Publication date: January 21, 2016
    Inventors: Marie-Angelique CAZALIS, Maud TOURNOUD, Fabienne VENET, Alain LEPAPE, Guillaume MONNERET
  • Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS
    Patent number: 9110079
    Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: August 18, 2015
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON (HCL)
    Inventors: Marie-Angélique Cazalis, Alexandre Pachot, Sylvie Tissot, Guillaume Monneret
  • METHOD AND KIT FOR ESTABLISHING AN IN VITRO PROGNOSIS ON A PATIENT EXHIBITING SIRS
    Publication number: 20120077693
    Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 29, 2012
    Applicants: HOSPICES CIVILS DE LYON (HCL), BIOMERIEUX
    Inventors: Marie-Angélique CAZALIS, Alexandre PACHOT, Sylvie TISSOT, Guillaume MONNERET
  • METHODS FOR DETERMINING A PATIENT'S SUSCEPTIBILITY OF CONTRACTING A NOSOCOMIAL INFECTION AND FOR ESTABLISHING A PROGNOSIS OF THE PROGRESSION OF SEPTIC SYNDROME
    Publication number: 20110250592
    Abstract: A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.
    Type: Application
    Filed: January 18, 2010
    Publication date: October 13, 2011
    Applicants: HOSPICES CIVILS DE LYON (HCL), BIOMERIEUX
    Inventors: Marie-Angelique Cazalis, Alain Lepape, Guillaume Monneret, Bruno Mougin, Alexandre Pachot